ICL670

ApprovedSmall molecule

Novartis

ICL670 is one of 57 small molecule programs targeting Blood Transfusion. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blood TransfusionActive, not recruiting

Aplastic AnemiaActive, not recruiting

Blood TransfusionPhase 3

Active, not recruiting

Aplastic AnemiaApproved

Active, not recruiting

Competition

Competitive Landscape

70 competitors in Aplastic Anemia

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

2 2

Tepadina

Alnylam Pharmaceuticals

Phase 3

1 3

Busulfex

Akero Therapeutics

Phase 3

2 4

Alkeran

AApotex Inc.

Phase 3

2 5

Vepesid

AAvyxa

Phase 3

1 6

Paraplatin

AAvyxa

Phase 3

1 7

Neoral

Novartis

Phase 2

7 8

Promacta

GSK

Phase 2

6 9

Fludara

Sanofi

Phase 2

5 10

Atgam

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Concentration1 trial

Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).

Completed· Novartis logo

Novartis·Phase 2·NCT01090323·185 enrolled

Hematopoietic Stem Cell Transplantation1 trial

Post Hematopoietic Stem Cell Transplantation

Completed· Novartis logo

Novartis·Phase 4·NCT01610297·27 enrolled

Complication1 trial

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

Completed· Novartis logo

Novartis·Phase 2·NCT01044186·30 enrolled

Aplastic Anemia1 trial

Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients

Terminated· Novartis logo

Novartis·Phase 4·NCT01818726·15 enrolled

Blood Transfusion1 trial

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

Completed· Novartis logo

Novartis·Phase 3·NCT00061750·595 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ICL670. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ICL670 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ICL670. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

ICL670

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Concentration1 trial

Hematopoietic Stem Cell Transplantation1 trial

Complication1 trial

Aplastic Anemia1 trial

Blood Transfusion1 trial

References

Drug Info

Quick Facts

Related News